1-7 of 7
Joel D. Leverson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Expanding the Repertoire for “Large Small Molecules”: Prodrug ABBV-167 Efficiently Converts to Venetoclax with Reduced Food Effect in Healthy Volunteers

Ahmed Hamed Salem, Zhi-Fu Tao, Orlando F. Bueno, Jie Chen, Shuang Chen, Rohinton Edalji, Steven W. Elmore, Keith M. Fournier, Kaid C. Harper, Richard Hong, Gary J. Jenkins, Jianguo Ji, Russell A. Judge, John C. Kalvass, Russell C. Klix, Yi-Yin Ku, Joel D. Leverson, Richard A. Marks, Kennan C. Marsh, Rajeev M. Menon, Chang H. Park, Darren C. Phillips, Yu-Ming Pu, Saul H. Rosenberg, Yeshwant D. Sanzgiri, Ahmad Y. Sheikh, Yi Shi, Deanne Stolarik, Ahmed A. Suleiman, Xilu Wang, Geoff G.Z. Zhang, Nathaniel D. Catron, Andrew J. Souers
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (6): 999–1008.
DOI: https://doi.org/10.1158/1535-7163.MCT-21-0077
Published: 01 June 2021
View article
PDF
Includes: Supplementary data
Journal Articles

Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo

Jason J. Zoeller, Aleksandr Vagodny, Krishan Taneja, Benjamin Y. Tan, Neil O'Brien, Dennis J. Slamon, Deepak Sampath, Joel D. Leverson, Roderick T. Bronson, Deborah A. Dillon, Joan S. Brugge
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (6): 1115–1126.
DOI: https://doi.org/10.1158/1535-7163.MCT-18-0743
Published: 03 June 2019
View article
PDF
Includes: Supplementary data
Journal Articles

Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness

Claudia Iavarone, Ioannis K. Zervantonakis, Laura M. Selfors, Sangeetha Palakurthi, Joyce F. Liu, Ronny Drapkin, Ursula A. Matulonis, Dorothy Hallberg, Victor E. Velculescu, Joel D. Leverson, Deepak Sampath, Gordon B. Mills, Joan S. Brugge
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (3): 642–655.
DOI: https://doi.org/10.1158/1535-7163.MCT-18-0413
Published: 01 March 2019
View article
PDF
Includes: Supplementary data
Journal Articles

Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

Elizabeth A. Punnoose, Joel D. Leverson, Franklin Peale, Erwin R. Boghaert, Lisa D. Belmont, Nguyen Tan, Amy Young, Michael Mitten, Ellen Ingalla, Walter C. Darbonne, Anatol Oleksijew, Paul Tapang, Peng Yue, Jason Oeh, Leslie Lee, Sophie Maiga, Wayne J. Fairbrother, Martine Amiot, Andrew J. Souers, Deepak Sampath
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2016) 15 (5): 1132–1144.
DOI: https://doi.org/10.1158/1535-7163.MCT-15-0730
Published: 05 May 2016
View article
PDF
Includes: Supplementary data
Journal Articles

MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor

Yu Xiao, Paul Nimmer, George S. Sheppard, Milan Bruncko, Paul Hessler, Xin Lu, Lisa Roberts-Rapp, William N. Pappano, Steven W. Elmore, Andrew J. Souers, Joel D. Leverson, Darren C. Phillips
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (8): 1837–1847.
DOI: https://doi.org/10.1158/1535-7163.MCT-14-0928
Published: 05 August 2015
View article
PDF
Includes: Supplementary data
Journal Articles

The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo

Jun Chen, Sha Jin, Vivek Abraham, Xiaoli Huang, Bernard Liu, Michael J. Mitten, Paul Nimmer, Xiaoyu Lin, Morey Smith, Yu Shen, Alexander R. Shoemaker, Stephen K. Tahir, Haichao Zhang, Scott L. Ackler, Saul H. Rosenberg, Heather Maecker, Deepak Sampath, Joel D. Leverson, Chris Tse, Steven W. Elmore
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (12): 2340–2349.
DOI: https://doi.org/10.1158/1535-7163.MCT-11-0415
Published: 07 December 2011
View article
PDF
Includes: Supplementary data
Journal Articles

Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo

Yan Luo, Alexander R. Shoemaker, Xuesong Liu, Keith W. Woods, Sheela A. Thomas, Ron de Jong, Edward K. Han, Tongmei Li, Vincent S. Stoll, Jessica A. Powlas, Anatol Oleksijew, Michael J. Mitten, Yan Shi, Ran Guan, Thomas P. McGonigal, Vered Klinghofer, Eric F. Johnson, Joel D. Leverson, Jennifer J. Bouska, Mulugeta Mamo, Richard A. Smith, Emily E. Gramling-Evans, Bradley A. Zinker, Amanda K. Mika, Phong T. Nguyen, Tilman Oltersdorf, Saul H. Rosenberg, Qun Li, Vincent L. Giranda
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2005) 4 (6): 977–986.
DOI: https://doi.org/10.1158/1535-7163.MCT-05-0005
Published: 14 June 2005
View article
PDF